Probiotics will lead microbiome therapeutics sales through 2036 with 41.2% share of the product type segment in 2026, driven by expanding clinical protocols and institutional procurement requirements. The market was valued at USD 0.3 billion in 2025 and is expected to be worth USD 5.9 billion by 2036.